Revenue up 2.4% but PBT collapsed 101% as H2 swung to a NZD 15.9m loss

PBT is the cleaner operating read because the tax line flipped (effective rate of -30.2% versus +29.3% prior) and adds 0.6 percentage points of headline distortion to the NPAT growth gap.

The interim release showed H1 NPAT of NZD 15.4m, which means H2 swung to an implied NZD 15.9m loss on H2 revenue of NZD 282.2m. Operating cash inflow halved to NZD 37.8m, and the group moved from a NZD 8.4m net cash position to NZD 38.7m net debt as gross borrowings rose from NZD 12.5m to NZD 58.9m. No final dividend was declared, so the FY24 payout is the 1.75 cps interim only, half FY23's 3.5 cps total.

• Revenue rose 2.4% (and management cites group sales up 3.8% including Bevilles), yet PBT fell from NZD 49.7m to roughly break-even. That is a major operating-leverage failure: incremental revenue did not drop through, implying gross margin and/or operating cost pressure that the release does not quantify directly. Comparable EBIT was guided to be "in line with analysts' expectations", but the statutory outcome is a loss.
• Cash conversion deteriorated sharply. OCF fell 52.8% to NZD 37.8m and FCF pre-lease fell from NZD 53.6m to NZD 16.7m, even though inventory was reduced by NZD 7.5m and capex was cut 20.3% to NZD 21.1m (3.3% of revenue). The cash decline is therefore being driven by lost earnings, not working-capital build, which is the harder problem to reverse.
• Balance sheet is now carrying the result. Equity fell 11.5% to NZD 166.9m and gross borrowings rose 371% to NZD 58.9m, swinging the group to NZD 38.7m net debt. The NZD 46.4m increase in drawn debt is materially larger than retained FCF could fund, indicating debt absorbed dividends, working capital, and any non-trading outflows. ROE went from 18.6% to -0.3%.

Management noted FY24 Group comparable EBIT was expected to be in line with analyst expectations, and pointed to "positive sales momentum across all markets" with H2 group sales up 4.9% and June-quarter sales up 6%. That sales-line commentary is at odds with the statutory profit and cash outcome, which means the gap to watch is whether the FY25 starting trajectory translates the sales recovery into restored gross margin and cash conversion, or whether the H2 cost base is now structurally elevated. The release does not resolve which of those two paths is operative.

First, the move from NZD 35.2m NPAT to a small loss came alongside revenue growth, which means the deterioration sits in margin and operating costs rather than volume — a more durable problem than a one-off. Second, the only items flattering the cash result are the NZD 7.5m inventory reduction and the NZD 5.4m lower capex; even with those, OCF still halved, so the underlying cash earnings deterioration is larger than the headline OCF decline.

The dividend signal reinforces this read. Cutting the full-year payout from 3.5 cps to 1.75 cps while drawing NZD 46.4m of additional debt is consistent with the board protecting liquidity rather than smoothing through a transient dip. The release flags no specifically disclosed non-recurring items that would explain away the PBT collapse, so on the information provided this is the run-rate exit position, not a clean one-off.

This briefing cannot assess gross margin, segment-level performance, or the contribution of the Bevilles acquisition because none of those are quantified in the supplied disclosure.